Daiichi Sankyo Enters Europe's Cholesterol Market
Nilemdo and Nustendi Approved
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
You may also be interested in...
Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.